Compare COLD & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | SYRE |
|---|---|---|
| Founded | 1903 | 2013 |
| Country | United States | United States |
| Employees | 12690 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 2009 | 2015 |
| Metric | COLD | SYRE |
|---|---|---|
| Price | $12.20 | $68.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $15.17 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 3.7M | 1.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,601,846,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $12.29 |
| 52 Week High | $20.30 | $75.00 |
| Indicator | COLD | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 69.89 |
| Support Level | $11.98 | $30.39 |
| Resistance Level | $12.24 | $75.00 |
| Average True Range (ATR) | 0.36 | 4.60 |
| MACD | 0.08 | 1.13 |
| Stochastic Oscillator | 53.10 | 78.00 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.